论文部分内容阅读
肝癌是我国常见的恶性肿瘤之一,在东南沿海一带发病率尤高。由于多合并肝硬化和早期肝癌即有肝内播散,故手术切除的机会较少。我国曾统计3254例,其中能手术切除的只占5.3%。将近95%的病例确诊时已失去手术机会。而且对肝癌的治疗,临床常采用手术切除、肝动脉插管化疗+栓塞、局部注射等治疗手段。但对中、晚期肝癌(Ⅱ～Ⅲ期)临床上常束手无策,尤其是多发性肝癌伴门静脉癌栓形成的病人,预后极差。因此,寻求治疗肝癌的新方法和新药物已成为急待解决的问题。自2000年2月起,我们应用健择(CEMZAR)+顺铂(DDP)联合方案治疗晚期肝癌(Ⅲ期)8例,收到了近期较好的效果。现将结果报告如下:
Liver cancer is one of the most common malignancies in China, with a particularly high incidence in the southeast coastal areas. Due to multiple liver cirrhosis and early hepatocellular carcinoma with intrahepatic spread, there is less chance of surgical resection. 3254 cases have been counted in China, of which only 5.3% can be surgically removed. Nearly 95% of cases have lost surgery when they are diagnosed. And for the treatment of liver cancer, clinical often used surgical resection, hepatic artery catheterization chemotherapy + embolization, local injection and other treatment. However, in the middle and late stages of liver cancer (II ~ III) often do nothing, especially in patients with multiple liver cancer with portal vein tumor thrombosis, the prognosis is very poor. Therefore, the search for new methods and new drugs for the treatment of liver cancer has become an urgent problem to be solved. Since February 2000, we have applied the combination of CEMZAR and DDP in the treatment of advanced hepatocellular carcinoma (stage III) in 8 cases and received good results in the near future. The results reported below: